MRD-directed Therapy for Low-risk and Intermediate-risk AML.

NCT02870777 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

743

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Minimal Residual Disease

Interventions

COMBINATION_PRODUCT: MRD-directed therapy

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]